Leire Burgos

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

Bruno Paiva, Noemí Puig, María‐Teresa Cedena et al. · Journal of Clinical Oncology · 2019 · 276 citations · Full text

Medicine, Hematology, Oncology +17

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Ibai Goicoechea, Noemí Puig, María‐Teresa Cedena et al. · Blood · 2020 · 133 citations · Full text

Medicine, Cancer Biology, Oncology +17

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

Luzalba Sanoja-Flores, Juan Flores‐Montero, Juan‐José Garcés et al. · Blood Cancer Journal · 2018 · 124 citations · Full text

Medicine, Hematology, Oncology +17

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

Juan‐José Garcés, María‐Teresa Cedena, Noemí Puig et al. · Journal of Clinical Oncology · 2022 · 114 citations · Full text

Medicine, Hematology, Oncology +17

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

Bruno Paiva, Luís A. Corchete, María‐Belén Vídriales et al. · Blood · 2016 · 106 citations · Full text

Medicine, Cell Biology, Oncology +14